Fabry disease

R Schiffmann - Handbook of clinical neurology, 2015 - Elsevier
Fabry disease, an X-linked disorder of glycosphingolipids that is caused by mutations of the
GLA gene that codes for α-galactosidase A, leads to dysfunction of many cell types and …

[HTML][HTML] Prevalence rate of laboratory defined aspirin resistance in cardiovascular disease patients: A systematic review and meta-analysis

P Ebrahimi, Z Farhadi, M Behzadifar… - Caspian Journal of …, 2020 - ncbi.nlm.nih.gov
Background: Cardiovascular disease (CVD) is the first cause of mortality worldwide, with all
the healthcare systems facing this very challenging issue. Aspirin continues to be the major …

Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing

MK Freynhofer, SC Gruber, EL Grove… - Thrombosis and …, 2015 - thieme-connect.com
Platelets are key players in atherothrombosis. Antiplatelet therapy comprising aspirin alone
or with P2Y 12-inhibitors are effective for prevention of atherothrombotic complications …

Fabry disease: a disorder of childhood onset

R Schiffmann, M Ries - Pediatric neurology, 2016 - Elsevier
Background Fabry disease, an X-linked disorder of glycosphingolipids, markedly increases
the risk of systemic vasculopathy, ischemic stroke, small-fiber peripheral neuropathy, cardiac …

Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease

JW Zhang, WW Liu, TA McCaffrey, XQ He… - … Interventions in Aging, 2017 - Taylor & Francis
Objectives Previous studies have illustrated the link between high on-aspirin platelet
reactivity (HAPR) with increasing thrombotic risks. The aim of our study was to investigate …

[PDF][PDF] Prevalence of high on-treatment platelet reactivity in patients with chronic kidney disease treated with acetylsalicylic acid for stroke prevention

M Horyniecki, B Łącka-Gaździk, E Niewiadomska… - Arch Intern …, 2018 - ppm.edu.pl
RESULTS No significant differences were observed in the prevalence of HOPR between
patients with and without CKD. Patients with CKD and HOPR measured by ASPItest had …

Evaluating Effectiveness and Safety in Chronic Kidney Disease with Atrial Flutter Using an Anticoagulation Strategy

YT Wang, CY Chen, MJ Bair - Medicina, 2020 - mdpi.com
Background and objectives: Recent randomized trials of oral antithrombotic drugs with atrial
flutter (AFL) excluded patients with renal impairment because of their increased risk of …

[PDF][PDF] Прогнозирование исходов хронической болезни почек у больных с сердечно-сосудистой патологией в старческом возрасте

ВМ Гусева - 2016 - samsmu.ru
Демографические изменения, происходящие в последние десятилетия в Российской
Федерации, как и во многих других странах мира, характеризуются увеличением доли …

A hatásos trombocita aggregáció gátlás jelentősége szervátültetést követően

Á Varga - 2015 - search.proquest.com
A szervátültetés története, szervek és testrészek egyik emberből, másik emberbe, vagy
állatból emberbe történő átvitele évezredekre nyúlik vissza. Az egyik legkorábbi és talán a …

[PDF][PDF] ОСОБЕННОСТИ СЕРДЕЧНО-СОСУДИСТОЙ ПАТОЛОГИИ У ПАЦИЕНТОВ СТАРЧЕСКОГО ВОЗРАСТА, СТРАДАЮЩИХ ХРОНИЧЕСКОЙ БОЛЕЗНЬЮ …

ВМ ГУСЕВА - 2015 - samsmu.ru
В последние десятилетия во многих странах мира, в том числе и в Российской
Федерации, происходят демографические изменения, характеризующиеся …